Vet Med - Czech, 2013, 58(3):113-185 | DOI: 10.17221/6746-VETMED

Antiviral agents targeting the influenza virus: a review and publication analysisReview

L. Eyer, K. Hruska
Veterinary Research Institute, Brno, Czech Republic

Influenza is a serious infectious disease, which is life-threatening especially in children, seniors and immunocompromised patients. In addition to vaccination, the development of new anti-influenza agents represents a crucial defence strategy to combat seasonal and pandemic influenza strains. At present most attention is paid to the development of inhibitors of influenza neuraminidase, which has been established as a key drug target for the prophylaxis and treatment of influenza infections. However, the emergence of drug-resistant influenza variants highlights the need of continuously innovative strategies for the development of new drugs with improved antiviral effects, higher safety and increased tolerability. In this review article, an analysis of publications describing anti-influenza agents indexed in the Web of Science® database has been carried out. The most important publications are presented in tables and are characterised by several key words, abstracts and references. The presented publications have been sorted according to five basic criteria: (i) review articles, (ii) design, synthesis and evaluation of new anti-influenza drugs, (iii) major classes of anti-influenza drugs, (iv) combination therapy of influenza infections and (v) influenza drug resistance. The design of this review article allows us to offer a complex overview of known antiviral agents targeting influenza viruses, facilitates easy and rapid orientation in numerous publications written on this subject, and aids the gathering of required data.

Keywords: influenza; virus; antiviral; agents; drug; resistance; therapy; structure-based drug design

Published: March 31, 2013  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Eyer L, Hruska K. Antiviral agents targeting the influenza virus: a review and publication analysis. Vet Med-Czech. 2013;58(3):113-185. doi: 10.17221/6746-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aggarwal S, Dewhurst S, Takimoto T, Kim B (2011): Biochemical impact of the host adaptation-associated PB2 E627K mutation on the temperature-dependent RNA synthesis kinetics of influenza A virus polymerase complex. Journal of Biological Chemistry 286, 34504-34513. Go to original source... Go to PubMed...
    2. Al-qattan MN, Mordi MN (2010a): Docking of sialic acid analogues against influenza A hemagglutinin: a correlational study between experimentally measured and computationally estimated affinities. Journal of Molecular Modeling 16, 1047-1058. Go to original source... Go to PubMed...
    3. Al-qattan MN, Mordi MN (2010b): Site-directed fragment-based generation of virtual sialic acid databases against influenza A hemagglutinin. Journal of Molecular Modeling 16, 975-991. Go to original source... Go to PubMed...
    4. Atkins C, Evans CW, White EL, Noah JW (2012): Screening methods for influenza antiviral drug discovery. Expert Opinion on Drug Discovery 7, 429-438. Go to original source... Go to PubMed...
    5. Balannik V, Wang J, Ohigashi Y, Jing XH, Magavern E, Lamb RA, DeGrado WF, Pinto LH (2009): Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48, 11872-11882. Go to original source... Go to PubMed...
    6. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P (2006): Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Research 69, 39-45. Go to original source... Go to PubMed...
    7. Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina N, Prichard M, Babu YS (2010): A single intramuscular injection of peramivir demonstrates anti-influenza activity against recently isolated pandemic flu virus H1N1 (A/CA/04/2009). Antiviral Research 86, A29-A30. Go to original source...
    8. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO (2011): Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. Plos One 6. Go to original source...
    9. Barr IG, Deng YM, Iannello P, Hurt AC, Komadina N (2008): Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antiviral Research 80, 200-205. Go to original source... Go to PubMed...
    10. Basu D, Walkiewicz MP, Frieman M, Baric RS, Auble DT, Engel DA (2009): Novel influenza virus NS1 antagonists block replication and restore innate immune function. Journal of Virology 83, 1881-1891. Go to original source... Go to PubMed...
    11. Baughman BM, Slavish PJ, Dubois RM, Boyd VA, White SW, Webb TR (2012): Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. Acs Chemical Biology 7, 526-534. Go to original source... Go to PubMed...
    12. Beigel J, Bray M (2008): Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Research 78, 91-102. Go to original source... Go to PubMed...
    13. Boivin S, Cusack S, Ruigrok RWH, Hart DJ (2010): Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms. Journal of Biological Chemistry 285, 28411-28417. Go to original source... Go to PubMed...
    14. Bright RA, Medina MJ, Xu XY, Perez-Oronoz G, Wallis TR, Davis XHM, Povinelli L, Cox NJ, Klimov AI (2005): Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366, 1175-1181. Go to original source... Go to PubMed...
    15. Bright RA, Shay D, Bresee J, Klimov A, Cox N, Ortiz J (2006): High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season (Reprinted from MMWR, vol. 55, pg 44-46, 2006). Jama-Journal of the American Medical Association 295, 881-882. Go to original source...
    16. Cao B, Wang DY, Yu XM, We LQ, Pu ZH, Gao Y, Wang J, Dong JP, Li XL, Xu Q, Hu K, Chen BY, Yu YS, Song SF, Shu YL, Wang C (2012): An uncontrolled openlabel, multicenter study to monitor the antiviral activity and safety of inhaled zanamivir (as Rotadisk via Diskhaler device) among Chinese adolescents and adults with influenza-like illness. Chinese Medical Journal 125, 3002-3007.
    17. Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, Blanchon T, Leport C, Flahault A, Mentre F (2012): Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antiviral Therapy 17, 1085-1090. Go to original source... Go to PubMed...
    18. Cheng HM, Wan JT, Lin MI, Liu YX, Lu XY, Liu JS, Xu Y, Chen JX, Tu ZC, Cheng YSE, Ding K (2012): Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. Journal of Medicinal Chemistry 55, 2144-2153. Go to original source... Go to PubMed...
    19. Chintakrindi A, D'souza C, Kanyalkar M (2012): Rational development of neuraminidase inhibitor as novel antiflu drug. Mini-Reviews in Medicinal Chemistry 12, 1273-1281. Go to original source... Go to PubMed...
    20. Cianci C, Colonno RJ, Krystal M (1997): Differential effect of modified capped RNA substrates on influenza virus transcription. Virus Research 50, 65-75. Go to original source... Go to PubMed...
    21. Dai JP, Wang GF, Li WZ, Zhang L, Yang JC, Zhao XF, Chen XX, Xu YX, Li KS (2012): High-throughput screening for anti-influenza A virus drugs and study of the mechanism of procyanidin on influenza A virusinduced autophagy. Journal of Biomolecular Screening 17, 605-617. Go to original source... Go to PubMed...
    22. Davies WL, Hoffmann CE, Paulshock M, Wood TR, Haff RF, Grunert RR, Watts JC, Hermann EC, Neumayer EM, Mcgahen JW (1964): Antiviral activity of 1-adamantanamine (amantadine) . Science 144, 862-863. Go to original source... Go to PubMed...
    23. Deyde VM, Tung N, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV (2009): Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrobial Agents and Chemotherapy 53, 1039- 1047. Go to original source... Go to PubMed...
    24. Droebner K, Pleschka S, Ludwig S, Planz O (2011): Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Research 92, 195-203. Go to original source... Go to PubMed...
    25. Du QS, Wang SQ, Huang RB, Chou KC (2010): Computational 3D structures of drug-targeting proteins in the 2009-H1N1 influenza A virus. Chemical Physics Letters 485, 191-195. Go to original source...
    26. Du J, Cross TA, Zhou HX (2012): Recent progress in structure-based anti-influenza drug design. Drug Discovery Today 17, 1111-1120. Go to original source... Go to PubMed...
    27. Dudek SE, Luig C, Pauli EK, Schubert U, Ludwig S (2010): The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A Virus and vesicular stomatitis virus propagation by establishing an antiviral state. Journal of Virology 84, 9439-9451. Go to original source... Go to PubMed...
    28. Eleftheratos S, Spearpoint P, Ortore G, Kolocouris A, Martinelli A, Martin S, Hay A (2010): Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model. Bioorganic and Medicinal Chemistry Letters 20, 4182-4187. Go to original source... Go to PubMed...
    29. Eyer L, Hruska K (2012): Single-domain antibody fragments derived from heavy-chain antibodies: a review. Veterinarni Medicina 57, 439-513. Go to original source...
    30. Feng F, Miura N, Isoda N, Sakoda Y, Okamatsu M, Kida H, Nishimura SI (2010): Novel trivalent anti-influenza reagent. Bioorganic and Medicinal Chemistry Letters 20, 3772-3776. Go to original source... Go to PubMed...
    31. Fukuoka M, Minakuchi M, Kawaguchi A, Nagata K, Kamatari YO, Kuwata K (2012): Structure-based discovery of anti-influenza virus A compounds among medicines. Biochimica et Biophysica Acta-General Subjects 1820, 90-95. Go to original source... Go to PubMed...
    32. Fukushi M, Yamashita M, Miyoshi-Akiyama T, Kubo S, Yamamoto K, Kudo K (2012): Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 virus. Plos One 7. Go to original source...
    33. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K (2002): In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial Agents and Chemotherapy 46, 977-981. Go to original source... Go to PubMed...
    34. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K (2005): Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy 49, 981-986. Go to original source... Go to PubMed...
    35. Galvao MGA, Santos MARC, da Cunha AJLA (2012): Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database of Systematic Reviews, vol. 23.
    36. Garcia J, Sovero M, Torres AL, Gomez J, Douce R, Barrantes M, Sanchez F, Jimenez M, Comach G, de Rivera I, Agudo R, Kochel T (2009): Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza and Other Respiratory Viruses 3, 69-74. Go to original source... Go to PubMed...
    37. Gauld NJ, Jennings LC, Frampton C, Huang QS (2012): Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling. Journal of Antimicrobial Chemotherapy 67, 2949-2956. Go to original source... Go to PubMed...
    38. Ge H, Wang YF, Xu J, Gu Q, Liu HB, Xiao PG, Zhou JJ, Liu YH, Yang ZR, Su H (2010): Anti-influenza agents from traditional Chinese medicine. Natural Product Reports 27, 1758-1780. Go to original source... Go to PubMed...
    39. Giannecchini S, Wise HM, Digard P, Clausi V, Del Poggetto E, Vesco L, Puzelli S, Donatelli I, Azzi A (2011): Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules. Antiviral Research 92, 64-72. Go to original source... Go to PubMed...
    40. Goktas F, Vanderlinden E, Naesens L, Cesur N, Cesur Z (2012): Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4azaspiro[4.5]decan-4-yl)carboxamide derivatives. Bioorganic and Medicinal Chemistry 20, 7155-7159. Go to original source... Go to PubMed...
    41. Gong JZ, Xu WF (2008): Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor. Current Medicinal Chemistry 15, 3145-3159. Go to original source... Go to PubMed...
    42. Gong JZ, Fang H, Li MY, Liu Y, Yang KH, Liu YZ, Xu WF (2009): Potential targets and their relevant inhibitors in anti-influenza fields. Current Medicinal Chemistry 16, 3716-3739. Go to original source... Go to PubMed...
    43. Govorkova EA, Webster RG (2010): Combination chemotherapy for influenza. Viruses-Basel 2, 1510-1529. Go to original source... Go to PubMed...
    44. Govorkova EA, Fang HB, Tan M, Webster RG (2004): Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrobial Agents and Chemotherapy 48, 4855-4863. Go to original source... Go to PubMed...
    45. Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A (2000): The anti-influenza virus ahent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. Journal of Virology 74, 11108-11114. Go to original source... Go to PubMed...
    46. Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM (2012): Influenza neuraminidase: A druggable target for natural products. Natural Product Reports 29, 11-36. Go to original source... Go to PubMed...
    47. Guinea R, Carrasco L (1994): Concanamycin-A blocks influenza-virus entry into cells under acidic conditions. Febs Letters 349, 327-330. Go to original source... Go to PubMed...
    48. Haasbach E, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O (2011): Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Research 91, 304-313. Go to original source... Go to PubMed...
    49. Hanson BJ, Boon ACM, Lim APC, Webb A, Ooi EE, Webby RJ (2006): Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research 7, 126. Go to original source... Go to PubMed...
    50. Hastings JC, Selnick H, Wolanski B, Tomassini JE (1996): Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrobial Agents and Chemotherapy 40, 1304-1307. Go to original source... Go to PubMed...
    51. He G, Massarella J, Ward P (1999): Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clinical Pharmacokinetics 37, 471-484. Go to original source... Go to PubMed...
    52. He J, Qi WB, Tian J, Jiao PR, Liu GQ, Zhang CH, Liao M (2012): Amaryllidaceae alkaloids exhibit anti-influenza activity in MDCK cells, an investigation of Amaryllidaceae alkaloids and MDCK cells insight. Journal of Animal and Veterinary Advances 11, 2485-2492. Go to original source...
    53. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS (2004): Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets. Journal of Infectious Diseases 190, 1627-1630. Go to original source... Go to PubMed...
    54. Hoffman LR, Kuntz ID, White JM (1997): Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: Irreversible inhibition of infectivity. Journal of Virology 71, 8808-8820. Go to original source... Go to PubMed...
    55. Hosoya M, Matsuyama S, Baba M, Suzuki H, Shigeta S (1992): Effects of protease inhibitors on replication of various myxoviruses. Antimicrobial Agents and Chemotherapy 36, 1432-1436. Go to original source... Go to PubMed...
    56. Hosoya M, Shigeta S, Ishii T, Suzuki H, Declercq E (1993): Comparative inhibitory effects of various nucleoside and nonnucleoside analogs on replication of influenza-virus type-A and type-B in-vitro and inovo. Journal of Infectious Diseases 168, 641-646. Go to original source... Go to PubMed...
    57. Hruska K, Franek M (2012): Sulfonamides in the environment: a review and a case report. Veterinarni Medicina 57, 1-35. Go to original source...
    58. Hruska K, Kaevska M (2012): Mycobacteria in water, soil, plants and air: a review. Veterinarni Medicina 57, 623-679. Go to original source...
    59. Hsieh HP, Hsu JTA (2007): Strategies of development of antiviral agents directed against influenza virus replication. Current Pharmaceutical Design 13, 3531- 3542. Go to original source... Go to PubMed...
    60. Hu YX, Jin Y, Han DP, Zhang GZ, Cao SP, Xie JJ, Xue J, Li Y, Meng D, Fan XX, Sun LQ, Wang M (2012): Mast cell-induced lung injury in mice infected with H5N1 influenza virus. Journal of Virology 86, 3347-3356. Go to original source... Go to PubMed...
    61. Hung HC, Liu CL, Hsu JTA, Horng JT, Fang MY, Wu SY, Ueng SH, Wang MY, Yaw CW, Hou MH (2012): Development of an anti-influenza drug screening assay targeting nucleoproteins with tryptophan fluorescence quenching. Analytical Chemistry 84, 6391-6399. Go to original source... Go to PubMed...
    62. Ibanez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X (2011): Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. Journal of Infectious Diseases 203, 1063-1072. Go to original source... Go to PubMed...
    63. Intharathep P, Rungrotmongkol T, Decha P, Nunthaboot N, Kaiyawet N, Kerdcharoen T, Sompornpisut P, Hannongbua S (2011): Evaluating how rimantadines control the proton gating of the influenza A M2-proton port via allosteric binding outside of the M2-channel: MD simulations. Journal of Enzyme Inhibition and Medicinal Chemistry 26, 162-168. Go to original source... Go to PubMed...
    64. Iwai Y, Murakami K, Gomi Y, Hashimoto T, Asakawa Y, Okuno Y, Ishikawa T, Hatakeyama D, Echigo N, Kuzuhara T (2011): Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. Plos One 6. Go to original source...
    65. Jeong HJ, Ryu YB, Park SJ, Kim JH, Kwon HJ, Kim JH, Park KH, Rho MC, Lee WS (2009): Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorganic and Medicinal Chemistry 17, 6816-6823. Go to original source... Go to PubMed...
    66. Jiao GL, Yu GL, Wang W, Zhao XL, Zhang JZ, Ewart SH (2012): Properties of polysaccharides in several seaweeds from Atlantic Canada and their potential antiinfluenza viral activities. Journal of Ocean University of China 11, 205-212. Go to original source...
    67. Kaihatsu K, Barnard DL (2012): Recent developments in anti-influenza A virus drugs and use in combination therapies. Mini-Reviews in Organic Chemistry 9, 3-10. Go to original source...
    68. Kido H, Okumura Y, Yamada H, Le TQ, Yano M (2007): Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Current Pharmaceutical Design 13, 405-414. Go to original source... Go to PubMed...
    69. Kim CU, Lew W, Williams MA, Liu HT, Zhang LJ, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC (1997): Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 119, 681-690. Go to original source... Go to PubMed...
    70. Kim WY, Suh GY, Huh JW, Kim SH, Kim MJ, Kim YS, Kim HR, Ryu YJ, Han MS, Ko YG, Chon GR, Lee KH, Choi SH, Hong SB (2011): Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically Ill patients on mechanical ventilation. Antimicrobial Agents and Chemotherapy 55, 5703- 5709. Go to original source... Go to PubMed...
    71. Kinger M, Park YD, Park JH, Hur MG, Jeong HJ, Park SJ, Lee WS, Kim SW, Yang SD (2012): Design, synthesis, and anti-influenza viral activities of 1,3-diarylprop-2-en-1-ones: A novel class of neuraminidase inhibitors. Archives of Pharmacal Research 35, 633- 638. Go to original source... Go to PubMed...
    72. Kongkamnerd J, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Miertus S, De-Eknamkul W (2012): A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. Journal of Enzyme Inhibition and Medicinal Chemistry 27, 5-11. Go to original source... Go to PubMed...
    73. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang YH, Gao QS, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JAT, Palese P, Shaw ML, Chanda SK (2010): Human host factors required for influenza virus replication. Nature 463, 813-817. Go to original source... Go to PubMed...
    74. Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OHJ, Ruigrok RWH, Cusack S (2012): Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) Polymerase. Plos Pathogens 8. Go to original source... Go to PubMed...
    75. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M (2010): Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrobial Agents and Chemotherapy 54, 1256-1264. Go to original source... Go to PubMed...
    76. Larson AM, Wang HM, Cao Y, Jiang TJ, Chen JZ, Klibanov A (2012): Conjugating drug candidates to polymeric chains does not necessarily enhance anti-influenza activity. Journal of Pharmaceutical Sciences 101, 3896- 3905. Go to original source... Go to PubMed...
    77. Lee KK, Pessi A, Gui L, Santoprete A, Talekar A, Moscona A, Porotto M (2011): Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. Journal of Biological Chemistry 286, 42141-42149. Go to original source... Go to PubMed...
    78. Li Y, Zhang XZ, Wang XY, Li S, Ruan JX, Zhang ZQ (2009): Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 877, 933-938. Go to original source... Go to PubMed...
    79. Li L, Chang SH, Xiang JF, Li Q, Liang HH, Tang YL, Liu YF (2012a): NMR identification of anti-influenza lead compound targeting at PA(C) subunit of H5N1 polymerase. Chinese Chemical Letters 23, 89-92. Go to original source...
    80. Li L, Chang SH, Xiang JF, Li Q, Liang HH, Tang YL, Liu YF (2012b): Screen anti-influenza lead compounds that target the PA(C) subunit of H5N1 viral RNA polymerase. Plos One 7. Go to original source...
    81. Liu HX, Yao XJ, Wang CQ, Han JA (2010): In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Molecular Pharmaceutics 7, 894-904. Go to original source... Go to PubMed...
    82. Liu KC, Fang JM, Jan JT, Cheng TJR, Wang SY, Yang ST, Cheng YSE, Wong CH (2012): Enhanced anti-influenza agents conjugated with anti-inflammatory activity. Journal of Medicinal Chemistry 55, 8493-8501. Go to original source... Go to PubMed...
    83. Ludwig S, Planz O, Pleschka S, Wolff T (2003): Influenzavirus-induced signaling cascades: targets for antiviral therapy? Trends in Molecular Medicine 9, 46-52. Go to original source... Go to PubMed...
    84. Luo GX, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M (1997): Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. Journal of Virology 71, 4062-4070. Go to original source... Go to PubMed...
    85. Lv HM, Guo XL, Gu RX, Wei DQ (2011): Free energy calculations and binding analysis of two potential antiinfluenza drugs with polymerase basic protein-2 (PB2). Protein and Peptide Letters 18, 1002-1009. Go to original source... Go to PubMed...
    86. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F (2006): Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents and Chemotherapy 50, 1470-1479. Go to original source... Go to PubMed...
    87. Marra A, Moni L, Pazzi D, Corallini A, Bridi D, Dondoni A (2008): Synthesis of sialoclusters appended to calix[4]arene platforms via multiple azide-alkyne cycloaddition. New inhibitors of hemagglutination and cytopathic effect mediated by BK and influenza A viruses. Organic and Biomolecular Chemistry 6, 1396- 1409. Go to original source... Go to PubMed...
    88. Martinez O, Tsibane T, Basler CF (2009): Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. International Reviews of Immunology 28, 69-92. Go to original source... Go to PubMed...
    89. Masihi KN, Schweiger B, Finsterbusch T, Hengel H (2007): Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza a virus infections in mice. Journal of Chemotherapy 19, 295- 303. Go to original source... Go to PubMed...
    90. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A (2000): The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. Journal of Clinical Pharmacology 40, 836-843. Go to original source... Go to PubMed...
    91. Masuda T, Yoshida S, Arai M, Kaneko S, Yamashita M, Honda T (2003): Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidinoNeu5Ac2en derivatives. Chemical and Pharmaceutical Bulletin 51, 1386-1398. Go to original source... Go to PubMed...
    92. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004): Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Journal of Virology 78, 12665-12667. Go to original source... Go to PubMed...
    93. Miotto O, Heiny AT, Tan TW, August JT, Brusic V (2008): Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. Bmc Bioinformatics 9 (Suppl. 1), S18. Go to original source... Go to PubMed...
    94. Moss RB, Hansen C, Sanders RL, Hawley S, Li TJ, Steigbigel RT (2012): A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. Journal of Infectious Diseases 206, 1844- 1851. Go to original source... Go to PubMed...
    95. Muller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, Kainov DE (2012): Emerging cellular targets for influenza antiviral agents. Trends in Pharmacological Sciences 33, 89-99. Go to original source... Go to PubMed...
    96. Nacken W, Ehrhardt C, Ludwig S (2012): Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses. Biological Chemistry 393, 525-534. Go to original source... Go to PubMed...
    97. Nakazawa M, Kadowaki SE, Watanabe I, Kadowaki Y, Takei M, Fukuda H (2008): PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Research 78, 194-201. Go to original source... Go to PubMed...
    98. Narla SN, Sun XL (2012): Immobilized sialyloligo-macroligand and its protein binding specificity. Biomacromolecules 13, 1675-1682. Go to original source... Go to PubMed...
    99. Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT (2012): Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A Viruses. Plos One 7. Go to original source...
    100. Ochiai H, Sakai S, Hirabayashi T, Shimizu Y, Terasawa K (1995): Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza-A and influenza-B viruses in Mdck cells. Antiviral Research 27, 425-430. Go to original source... Go to PubMed...
    101. Park SY, Kim S, Yoon H, Kim KB, Kalme SS, Oh S, Song CS, Kim DE (2011): Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Therapeutics 21, 395-402. Go to original source... Go to PubMed...
    102. Peng JX, Jiao JY, Li J, Wang W, Gu QQ, Zhu TJ, Li DH (2012): Pyronepolyene C-glucosides with NF-kappa B inhibitory and anti-influenza A viral (H1N1) activities from the sponge-associated fungus Epicoccum sp. JJY40. Bioorganic and Medicinal Chemistry Letters 22, 3188-3190. Go to original source... Go to PubMed...
    103. Pielak RM, Oxenoid K, Chou JJ (2011): Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure 19, 1655-1663. Go to original source... Go to PubMed...
    104. Ping JH, Keleta L, Forbes NE, Dankar S, Stecho W, Tyler S, Zhou Y, Babiuk L, Weingartl H, Halpin RA, Boyne A, Bera J, Hostetler J, Fedorova NB, Proudfoot K, Katzel DA, Stockwell TB, Ghedin E, Spiro DJ, Brown EG (2011): Genomic and protein structural maps of adaptive evolution of human influenza a virus to increased virulence in the mouse. Plos One 6. Go to original source...
    105. Pizzorno A, Abed Y, Boivin G (2011): Influenza drug resistance. Seminars in Respiratory and Critical Care Medicine 32, 409-422. Go to original source... Go to PubMed...
    106. Pontoriero A, Baumeister E, Campos AM, Savy VL (2011): Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008. Revista Panamericana de Salud Publica-Pan American Journal of Public Health 30, 634-640. Go to original source... Go to PubMed...
    107. Priyadarzini TRK, Selvin JFA, Gromiha MM, Fukui K, Veluraja K (2012): Theoretical investigation on the binding specificity of sialyldisaccharides with hemagglutinins of influenza A virus by molecular dynamics simulations. Journal of Biological Chemistry 287, 34547-34557. Go to original source... Go to PubMed...
    108. Quispe-Laime AM, Bracco JD, Barberio PA, Campagne CG, Rolfo VE, Umberger R, Meduri GU (2010): H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Medicine 36, 33-41. Go to original source... Go to PubMed...
    109. Rawat V, Dey S, Sudalai A (2012): Synthesis of the antiinfluenza agent (-)-oseltamivir free base and (-)-methyl 3-epi-shikimate. Organic and Biomolecular Chemistry 10, 3988-3990. Go to original source... Go to PubMed...
    110. Rosenberg MR, Casarotto MG (2010): Coexistence of two adamantane binding sites in the influenza A M2 ion channel. Proceedings of the National Academy of Sciences of the United States of America 107, 13866-13871. Go to original source... Go to PubMed...
    111. Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, Suzuki H (2003): Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. Journal of Clinical Microbiology 41, 2164-2165. Go to original source... Go to PubMed...
    112. Sakurai J, Kikuchi T, Takahashi O, Watanabe K, Katoh T (2011): Enantioselective total synthesis of (+)-stachyflin: A potential anti-influenza a virus agent isolated from a microorganism. European Journal of Organic Chemistry 2948-2957. Go to original source...
    113. Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P (2006): Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Medical Microbiology and Immunology 195, 65-71. Go to original source... Go to PubMed...
    114. Schmidtke M, Schnittler U, Jahn B, Dahse HM, Stelzner A (2001): A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. Journal of Virological Methods 95, 133-143. Go to original source... Go to PubMed...
    115. Schnell JR, Chou JJ (2008): Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451, 591-595. Go to original source... Go to PubMed...
    116. Schulman JL, Palese P (1975): Susceptibility of different strains of influenza A virus to inhibitory effects of 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 63, 98-104. Go to original source... Go to PubMed...
    117. Sgarbanti R, Nencioni L, Amatore D, Coluccio P, Fraternale A, Sale P, Mammola CL, Carpino G, Gaudio E, Magnani M, Ciriolo MR, Garaci E, Palamara AT (2011): Redox regulation of the influenza hemagglutinin maturation process: A new cell-mediated strategy for anti-influenza therapy. Antioxidants and Redox Signaling 15, 593-606. Go to original source... Go to PubMed...
    118. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV (2010): Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Research 85, 354-360. Go to original source... Go to PubMed...
    119. Shie JJ, Fang JM, Lai PT, Wen WH, Wang SY, Cheng YSE, Tsai KC, Yang AS, Wong CH (2011): A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. Journal of the American Chemical Society 133, 17959-17965. Go to original source... Go to PubMed...
    120. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y (2003): High frequency of resistant viruses harboring different mutations in amantadinetreated children with influenza. Journal of Infectious Diseases 188, 57-61. Go to original source... Go to PubMed...
    121. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (2005): In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Research 68, 10-17. Go to original source... Go to PubMed...
    122. Sidwell RW, Smee DF (2000): In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Research 48, 1-16. Go to original source... Go to PubMed...
    123. Sigal GB, Mammen M, Dahmann G, Whitesides GM (1996): Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhanced binding through cooperative polyvalent interactions. Journal of the American Chemical Society 118, 3789-3800. Go to original source...
    124. Skehel JJ, Wiley DC (2000): Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annual Review of Biochemistry 69, 531-569. Go to original source... Go to PubMed...
    125. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW (2001): Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrobial Agents and Chemotherapy 45, 743-748. Go to original source... Go to PubMed...
    126. Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y (2010): Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice. Antimicrobial Agents and Chemotherapy 54, 126-133. Go to original source... Go to PubMed...
    127. Stamatiou G, Kolocouris A, Kolocouris N, Fytas G, Foscolos GB, Neyts J, De Clercq E (2001): Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus - identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Bioorganic and Medicinal Chemistry Letters 11, 2137-2142. Go to original source... Go to PubMed...
    128. Staschke KA, Hatch SD, Tang JC, Hornback WJ, Munroe JE, Colacino JM, Muesing MA (1998): Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology 248, 264-274. Go to original source... Go to PubMed...
    129. Stewart CR, Karpala AJ, Lowther S, Lowenthal JW, Bean AG (2011): Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. Plos One 6. Go to original source...
    130. Stimac A, Segota S, Sikiric MD, Ribic R, Frkanec L, Svetlicic V, Tomic S, Vranesic B, Frkanec R (2012): Surface modified liposomes by mannosylated conjugates anchored via the adamantyl moiety in the lipid bilayer. Biochimica et Biophysica Acta - Biomembranes 1818, 2252-2259. Go to original source... Go to PubMed...
    131. Stoner TD, Krauss S, Turner JCM, Seiler P, Negovetich NJ, Stallknecht DE, Frase S, Govorkova EA, Webster RG (2012): Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antiviral Research 93, 322-329. Go to original source... Go to PubMed...
    132. Sui HY, Zhao GY, Huang JD, Jin DY, Yuen KY, Zheng BJ (2009): Small interfering RNA targeting M2 gene induces effective and long term inhibition of influenza A virus replication. Plos One 4. Go to original source...
    133. Suzuki T, Takahashi T, Guo CT, Hidari KIPJ, Miyamoto D, Goto H, Kawaoka Y, Suzuki Y (2005): Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. Journal of Virology 79, 11705-11715. Go to original source... Go to PubMed...
    134. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ (1991): Virulence of rimantadine-resistant human influenza-A (H3N2) viruses in ferrets. Journal of Infectious Diseases 164, 969-972. Go to original source... Go to PubMed...
    135. Tado M, Abe T, Hatta T, Ishikawa M, Nakada S, Yokota T, Takaku H (2001): Inhibitory effect of modified 5'-capped short RNA fragments on influenza virus RNA polymerase gene expression. Antiviral Chemistry and Chemotherapy 12, 353-358. Go to original source... Go to PubMed...
    136. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF (2012): Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/ California/04/2009 (H1N1) virus infections in mice. Antiviral Research 94, 103-110. Go to original source... Go to PubMed...
    137. Tian L, Wang ZY, Wu H, Wang S, Wang Y, Wang YY, Xu JW, Wang LY, Qi FC, Fang ML, Yu DH, Fang XX (2011): Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo. Journal of Ethnopharmacology 137, 534-542. Go to original source... Go to PubMed...
    138. Tisdale M (2000): Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Reviews in Medical Virology 10, 45-55. Go to original source...
    139. Tisdale M, Ellis M, Klumpp K, Court S, Ford M (1995): Inhibition of influenza-virus transcription by 2'-deoxy-2'-fluoroguanosine. Antimicrobial Agents and Chemotherapy 39, 2454-2458. Go to original source... Go to PubMed...
    140. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, Singh SB, Tkacz JS, Goetz MA (1996): A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrobial Agents and Chemotherapy 40, 1189-1193. Go to original source... Go to PubMed...
    141. Tran L, Choi SB, Al-Najjar BO, Yusuf M, Wahab HA, Le L (2011): Discovery of potential M2 channel inhibitors based on the amantadine scaffold via virtual screening and pharmacophore modeling. Molecules 16, 10227- 10255. Go to original source... Go to PubMed...
    142. Ushirogawa H, Ohuchi M (2011): Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus. Virology Journal 8, 411. Go to original source... Go to PubMed...
    143. Vass M, Hruska K, Franek M (2008): Nitrofuran antibiotics: a review on the application, prohibition and residual analysis. Veterinarni Medicina 53, 469-500. Go to original source...
    144. Vergara-Jaque A, Poblete H, Lee EH, Schulten K, Gonzalez-Nilo F, Chipot C (2012): Molecular basis of drug resistance in A/H1N1 virus. Journal of Chemical Information and Modeling 52, 2650-2656. Go to original source... Go to PubMed...
    145. Wang XY, Li M, Zheng HY, Muster T, Palese P, Beg AA, Garcia-Sastre A (2000): Influenza A virus NS1 protein prevents activation of NF-kappa B and induction of alpha/beta interferon. Journal of Virology 74, 11566- 11573. Go to original source... Go to PubMed...
    146. Wang W, Zhang P, Yu GL, Li CX, Hao C, Qi X, Zhang LJ, Guan HS (2012): Preparation and anti-influenza A virus activity of kappa-carrageenan oligosaccharide and its sulphated derivatives. Food Chemistry 133, 880-888. Go to original source...
    147. Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJF, Mason AM, Nguyen V, Tucker SP, Wu WY (2004): Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorganic and Medicinal Chemistry Letters 14, 1589-1592. Go to original source... Go to PubMed...
    148. Wei GW, Meng WX, Guo HJ, Pan WQ, Liu JS, Peng T, Chen L, Chen CY (2011): Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. Plos One 6. Go to original source...
    149. Widjaja I, de Vries E, Tscherne DM, Garcia-Sastre A, Rottier PJM, de Haan CAM (2010): Inhibition of the ubiquitinproteasome system affects influenza A virus infection at a postfusion step. Journal of Virology 84, 9625-9631. Go to original source... Go to PubMed...
    150. Wong DDY, Choy KT, Chan RWY, Sia SF, Chiu HP, Cheung PPH, Chan MCW, Peiris JSM, Yen HL (2012): Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. Journal of Virology 86, 10558-10570. Go to original source... Go to PubMed...
    151. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC (2008): Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671. Go to original source... Go to PubMed...
    152. Wu Y, Li JQ, Kim YJ, Wu J, Wang Q, Hao Y (2011): In vivo and in vitro antiviral effects of berberine on influenza virus. Chinese Journal of Integrative Medicine 17, 444-452. Go to original source... Go to PubMed...
    153. Wu QF, Wang W, Dai XY, Wang ZY, Shen ZH, Ying HZ, Yu CH (2012): Chemical compositions and anti-influenza activities of essential oils from Mosla dianthera. Journal of Ethnopharmacology 139, 668-671. Go to original source... Go to PubMed...
    154. Yamada K, Koyama H, Hagiwara K, Ueda A, Sasaki Y, Kanesashi S, Ueno R, Nakamura HK, Kuwata K, Shimizu K, Suzuki M, Aida Y (2012): Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. Microbes and Infection 14, 740-747. Go to original source... Go to PubMed...
    155. Yanagita H, Yamamoto N, Fuji H, Liu XL, Ogata M, Yokota M, Takaku H, Hasegawa H, Odagiri T, Tashiro M, Hoshino T (2012): Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. Acs Chemical Biology 7, 552-562. Go to original source... Go to PubMed...
    156. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA (2006): Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. Journal of Virology 80, 8787-8795. Go to original source... Go to PubMed...
    157. Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N (1999): Identification of a novel HA conformational change inhibitor of human influenza virus. Archives of Virology 144, 865-878. Go to original source... Go to PubMed...
    158. Yoshimoto J, Yagi S, Ono J, Sugita K, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hashimoto N (2000): Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. Journal of Pharmacy and Pharmacology 52, 1247-1255. Go to original source... Go to PubMed...
    159. Zaraket H, Saito R, Suzuki Y, Suzuki Y, Caperig-Dapat I, Dapat C, Shabana II, Baranovich T, Suzuki H (2010): Genomic events contributing to the high prevalence of amantadine-resistant influenza A/H3N2. Antiviral Therapy 15, 307-319. Go to original source... Go to PubMed...
    160. Zarubaev VV, Golod EL, Anfimov PM, Shtro AA, Saraev VV, Gavrilov AS, Logvinov AV, Kiselev OI (2010): Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus. Bioorganic and Medicinal Chemistry 18, 839-848. Go to original source... Go to PubMed...
    161. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SSY, Lau SKP, Woo PCY, Chan KH, Jin DY, Yuen KY (2008): Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proceedings of the National Academy of Sciences of the United States of America 105, 8091-8096. Go to original source... Go to PubMed...
    162. Zhirnov OP, Klenk ND, Wright PF (2011): Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Research 92, 27-36. Go to original source... Go to PubMed...
    163. Zhou HB, Jin ML, Yu ZJ, Xu XJ, Peng YP, Wu HY, Liu JL, Liu H, Cao SB, Chen HC (2007): Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Research 76, 186-193. Go to original source... Go to PubMed...
    164. Zhu ZB, Li RM, Xiao GK, Chen ZP, Yang J, Zhu QH, Liu SW (2012): Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion. European Journal of Medicinal Chemistry 57, 211-216. Go to original source... Go to PubMed...
    165. Zoidis G, Fytas C, Papanastasiou L, Foscolos GB, Fytas G, Padalko E, De Clercq E, Naesens L, Neyts J, Kolocouris N (2006): Heterocyclic rimantadine analogues with antiviral activity. Bioorganic and Medicinal Chemistry 14, 3341-3348. Go to original source... Go to PubMed...
    166. Zu M, Yang F, Zhou WL, Liu AL, Du GH, Zheng LS (2012): In vitro anti-influenza virus and anti-inflammatory activities of the aflavin derivatives. Antiviral Research 94, 217-224. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content